Published on 20 August 2012
Statin generics: no differences in efficacy after switching
Author(s): Christoph Baumgärtel, MD, MSc
cardiovascular risk, generics, inferiority, potency, statins
DOI: 10.5639/gabij.2012.0103-4.032
18.164 views
Published on 20 August 2012
Author(s): Christoph Baumgärtel, MD, MSc
cardiovascular risk, generics, inferiority, potency, statins
DOI: 10.5639/gabij.2012.0103-4.032
18.164 views
Published on 02 August 2012
Author(s): Andy Gray, MScPharm, FPS, FFIP
generics policies, transparency, WHO policy
DOI: 10.5639/gabij.2012.0103-4.027
26.491 views
Published on 01 August 2012
Author(s): Luc Besançon
counterfeit medicines, healthcare professionals, risk communication
DOI: 10.5639/gabij.2012.0103-4.026
14.896 views
Published on 01 August 2012
Author(s): Keith McDonald, MSc, MRPharmS, Kowid Ho, PhD
biotechnological and chemical substances, drug substance quality, ICH Q11
DOI: 10.5639/gabij.2012.0103-4.025
35.796 views
Published on 01 August 2012
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2012.0102.024
5.283 views
Published on 04 July 2012
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2012.0102.022
7.789 views
Published on 03 July 2012
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2012.0102.015
12.089 views
Published on 03 July 2012
Author(s): Meenu Wadhwa, PhD, Robin Thorpe, PhD, FRCPath
comparability, guidelines, non-innovator biologic, quality, safety
DOI: 10.5639/gabij.2012.0103-4.023
31.551 views
Published on 03 July 2012
Author(s): Sabine Vogler, PhD, Nina Zimmermann, MA
competition, conference, generics policies, generics uptake, medicine prices, pricing, reimbursement
DOI: 10.5639/gabij.2012.0103-4.030
14.393 views
Published on 02 July 2012
Author(s): Susanne Keitel, MD
Council of Europe, counterfeit medicines, criminalization, falsified medicines, international treaty, MEDICRIME Convention
DOI: 10.5639/gabij.2012.0103-4.029
28.053 views
Published on 02 July 2012
Author(s): Matti Aapro, MD
biosimilars, cost burden, oncology
DOI: 10.5639/gabij.2013.0202.023
27.584 views
Published on 02 July 2012
Author(s): Sabine MJM Straus, MD, PhD, Thijs J Giezen, PharmD, PhD, MSc
biologicals, biosimilars, immunogenicity, pharmacovigilance, traceability
DOI: 10.5639/gabij.2012.0103-4.033
16.848 views